左西孟旦治疗急性心衰的疗效及对心功能、NT-proBNP、血清炎性指标的影响探讨  

Efficacy of levosimendan in the treatment of acute heart failure and its influence on cardiac function,NT-proBNP and serum inflammatory indexes

作　　者：刘杜萍 郭文晏 LIU Du-ping;GUO Wen-yan(Zhongshan Hospital Affiliated to Dalian University,Dalian 116001,China)

机构地区：[1]大连大学附属中山医院,116001

出　　处：《中国实用医药》2022年第22期108-110,共3页China Practical Medicine

摘　　要：目的分析左西孟旦治疗急性心力衰竭(心衰)的疗效及对心功能、N末端B型利钠肽原(NT-proBNP)、血清炎性指标的影响。方法90例急性心衰患者,按照奇偶法分为对照组和观察组,每组45例。对照组患者接受多巴酚丁胺治疗,观察组患者接受多巴酚丁胺联合左西孟旦治疗。比较两组患者治疗效果及治疗前后心功能指标[左室射血分数(LVEF)、左室舒张末期容积(LVEDV)、左室收缩末期容积(LVESV)]、NT-proBNP、血清炎性指标[白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)]水平。结果观察组患者治疗总有效率为93.33%,高于对照组的75.56%,差异具有统计学意义(P<0.05)。治疗后,观察组患者LVEF(50.42±6.38)%大于对照组的(46.71±6.62)%,LVEDV(121.46±52.03)ml、LVESV(66.56±21.57)ml均明显小于对照组的(139.36±54.38)、(78.05±22.67)ml,差异具有统计学意义(P<0.05)。治疗后,观察组患者NT-proBNP(904.83±21.97)pg/ml、IL-6(18.44±4.72)ng/L、hs-CRP(3.13±1.98)mg/L、Hcy(13.02±5.95)μmol/L均低于对照组的(975.77±22.36)pg/ml、(21.38±4.57)ng/L、(4.17±2.18)mg/L、(16.08±6.33)μmol/L,差异具有统计学意义(P<0.05)。结论左西孟旦治疗急性心衰能够提升临床效果,有效改善心功能、NT-proBNP及血清炎性指标,值得临床推广。Objective To analyze the efficacy of levosimendan in the treatment of acute heart failure and its influence on cardiac function,N-terminal pro-B-type natriuretic peptide(NT-proBNP)and serum inflammatory indexes.Methods A total of 90 patients with acute heart failure were divided into control group and observation group according to the odd-even method,with 45 cases in each group.Patients in the control group received dobutamine treatment,and patients in the observation group received dobutamine combined with levosimendan treatment.Both groups were compared in terms of therapeutic effect,cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic volume(LVEDV),left ventricular endsystolic volume(LVESV)],NT-proBNP,serum inflammatory markers[interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),homocysteine(Hcy)]level before and after treatment.Results The total effective rate of patients in the observation group was 93.33%,which was higher than 75.56%in the control group,and the difference was statistically significant(P<0.05).After treatment,the LVEF(50.42±6.38)%in the observation group was higher than(46.71±6.62)%in the control group;the LVEDV(121.46±52.03)ml and LVESV(66.56±21.57)ml in the observation group were significantly less than(139.36±54.38)and(78.05±22.67)ml in the control group;the differences were all statistically significant(P<0.05).After treatment,the NT-proBNP(904.83±21.97)pg/ml,IL-6(18.44±4.72)ng/L,hs-CRP(3.13±1.98)mg/L,Hcy(13.02±5.95)μmol/L in the observation group were lower than(975.77±22.36)pg/ml,(21.38±4.57)ng/L,(4.17±2.18)mg/L,(16.08±6.33)μmol/L in the control group,and the differences were all statistically significant(P<0.05).Conclusion Levosimendan in the treatment of acute heart failure can improve the clinical effect,effectively improve cardiac function,NT-proBNP and serum inflammatory indicators,which is worthy of clinical promotion.

关 键 词：左西孟旦 急性心力衰竭 心功能 N末端B型利钠肽原 炎性因子 

分 类 号：R541.6[医药卫生—心血管疾病]